Image pharmaphorum Editor Patients Welcome to ‘Generation R’ for the next decade of patient eng... Relationship recrudescence; inertia, cynicism and complacency must not prevail, says Nexgen Healthcare Communications’ Emma Sutcliffe Views & Analysis Lifestyle as medicine There’s nothing new about the idea that diet, exercise and other lifestyle factors impact our health and wellness. Views & Analysis Boosting trial recruitment through patient engagement Improving clinical trial recruitment has long been a priority for pharma, but despite having a plethora of new innovations at their disposal, along with a sincere commitment to patient cent Views & Analysis Designing digital solutions that drive adoption If any digital patient solution is to have an impact, adoption by its intended end users is critical. Load more results
Patients Welcome to ‘Generation R’ for the next decade of patient eng... Relationship recrudescence; inertia, cynicism and complacency must not prevail, says Nexgen Healthcare Communications’ Emma Sutcliffe
Views & Analysis Lifestyle as medicine There’s nothing new about the idea that diet, exercise and other lifestyle factors impact our health and wellness.
Views & Analysis Boosting trial recruitment through patient engagement Improving clinical trial recruitment has long been a priority for pharma, but despite having a plethora of new innovations at their disposal, along with a sincere commitment to patient cent
Views & Analysis Designing digital solutions that drive adoption If any digital patient solution is to have an impact, adoption by its intended end users is critical.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
